ScoreWhy is Krebs Biochemicals & Industries Ltd ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of -15.07% and Operating profit at 0% over the last 5 years
- The company has a negative book value of Rs 162.76 crore
2
The company has declared Negative results for the last 6 consecutive quarters
- NET SALES(9M) At Rs 18.25 cr has Grown at -40.03%
- PAT(9M) At Rs -11.61 cr has Grown at -40.03%
- CASH AND CASH EQUIVALENTS(HY) Lowest at Rs 0.13 cr
3
Risky - Negative EBITDA
- The company has recorded a negative EBITDA of Rs. -5.45 cr
- Over the past year, while the stock has generated a return of -34.98%, its profits have risen by 37.2%
- The stock is trading risky as compared to its average historical valuations
4
Underperformed the market in the last 1 year
- Even though the market (BSE500) generated negative returns of -4.42% in the last 1 year, its fall in the stock was much higher with a return of -34.98%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Krebs Biochem for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Krebs Biochem
-34.98%
-0.58
60.46%
Sensex
-10.34%
-0.79
13.08%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-15.07%
EBIT Growth (5y)
8.12%
EBIT to Interest (avg)
0
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.38
Sales to Capital Employed (avg)
0
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.50%
ROCE (avg)
-30.79%
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
33
Price to Book Value
-0.90
EV to EBIT
-31.28
EV to EBITDA
-68.13
EV to Capital Employed
5.99
EV to Sales
15.65
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-19.16%
ROE (Latest)
Negative BV
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend2What is working for the Company
PAT(Q)
Highest at Rs -2.34 cr.
EPS(Q)
Highest at Rs -1.09
-8What is not working for the Company
NET SALES(9M)
At Rs 18.25 cr has Grown at -40.03%
PAT(9M)
At Rs -11.61 cr has Grown at -40.03%
CASH AND CASH EQUIVALENTS(HY)
Lowest at Rs 0.13 cr
DEBTORS TURNOVER RATIO(HY)
Lowest at 0.00 times
Loading Valuation Snapshot...
Here's what is working for Krebs Biochem
Profit After Tax (PAT) - Quarterly
Highest at Rs -2.34 cr.
in the last five quartersMOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Earnings per Share (EPS) - Quarterly
Highest at Rs -1.09
in the last five quartersMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (Rs)
Here's what is not working for Krebs Biochem
Net Sales - Nine Monthly
At Rs 18.25 cr has Grown at -40.03%
Year on Year (YoY)MOJO Watch
Near term sales trend is very negative
Net Sales (Rs Cr)
Cash and Cash Equivalents - Half Yearly
Lowest at Rs 0.13 cr
in the last six half yearly periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Debtors Turnover Ratio- Half Yearly
Lowest at 0.00 times
in the last five half yearly periodsMOJO Watch
Company's pace of settling its Debtors has slowed
Debtors Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
